Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with ...

Pfizer executives are still bullish on the opportunity for its own obesity and diabetes drugs under development, eyeing a potential opening for oral versions and an improved safet ...

BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...

The chief scientific officer (CSO) is one of the most important C-suite roles in any biopharma organization. Pfizer's CSO is stepping down after a 15-year tenure. Management says its executive search ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

The prevalence of obesity continues to remain high in the US, making the demand for effective treatments even more urgent.

His presentation of 74 slides detailed Pfizer's (PFE) recent setbacks, including a trial failure for the company's oral obesity candidate danuglipron in December and the recent market recall of ...

Results from a phase 2b trial (ClinicalTrials.gov Identifier: NCT04707313) showed treatment with danuglipron led to statistically significant reductions in body weight at all tested doses (40mg ...